UK Markets close in 6 hrs 49 mins

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.17-2.50 (-5.36%)
At close: 04:00PM EDT
44.17 0.00 (0.00%)
After hours: 04:31PM EDT

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000

Full-time employees1,167

Key executives

NameTitlePayExercisedYear born
Dr. Stuart W. Peltz Ph.D.Co-Founder, CEO & Exec. Director1.64MN/A1960
Dr. Allan Steven Jacobson Ph.D.Co-Founder, Chairman of Scientific Advisory Board & Independent Director142.5kN/A1946
Ms. Emily Luisa HillChief Financial Officer814.34k1.2M1980
Dr. Neil Almstead Ph.D.Chief Technical Operations Officer810.82k4.12M1967
Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer824.09k355.34k1961
Mr. Eric PauwelsChief Bus. Officer810.47kN/A1961
Ms. Dawn A. SvoronosAdvisor62kN/A1953
Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MSChief Operating OfficerN/AN/A1972
Ms. Christine UtterSr. VP, Chief Accounting Officer & Head of People ServicesN/AN/A1978
Ms. Ellen Welch Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Corporate governance

PTC Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 5. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.